Micronase
$ 23,00 – $ 174,00Price range: $ 23,00 through $ 174,00
Minipress
$ 20,00 – $ 342,00Price range: $ 20,00 through $ 342,00
Mikacin Injection
$ 25,00 – $ 73,00Price range: $ 25,00 through $ 73,00
Mikacin Injection is a potent aminoglycoside antibiotic designed to treat serious bacterial infections caused by susceptible organisms. This medication is primarily utilized for managing severe systemic conditions such as bacteremia, septicemia, and respiratory tract infections. It demonstrates high efficacy against a broad range of Gram-negative bacteria, including various resistant strains. Mikacin is also indicated for the treatment of complex infections involving the central nervous system, bones, and joints. Additionally, it serves as a vital therapeutic option for intra-abdominal infections and serious skin or soft tissue complications.
Active substance: Amikacin
SKU:
Mikacin Injection
Category: Antibiotics
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Mikacin Injection – Information for Patients and Caregivers
Mikacin belongs to a class of antimicrobial medications known as aminoglycoside antibiotics. It is administered via parenteral injection to treat severe, systemic bacterial infections caused by susceptible Gram-negative microorganisms. Due to its potent pharmacological activity and specific toxicity profile, therapy requires precise dosing and clinical supervision under federal prescription regulations.
This clinical overview provides essential scientific information regarding the pharmacological characteristics, administration guidelines, and safety parameters of amikacin sulfate in inpatient and outpatient healthcare settings.
| Parameter | Clinical Description |
|---|---|
| Active ingredient | Amikacin sulfate |
| Therapeutic class | Aminoglycoside antibiotic |
| Route of administration | Intravenous (IV) infusion, Intramuscular (IM) injection |
| Prescription status | Prescription-only (Rx) |
| Primary purpose | Treatment of serious Gram-negative bacterial infections |
| Dosing approach | Individualized based on body weight and renal function |
How the drug works
Mikacin (amikacin sulfate) exerts its bactericidal action by irreversibly binding to the 30S ribosomal subunit of susceptible bacteria. This binding disrupts normal protein synthesis by causing misreading of messenger RNA (mRNA) and interfering with ribosomal translocation during translation. Consequently, nonfunctional proteins accumulate within the bacterial cell, compromising cell wall integrity and leading to cell death.
The antibacterial spectrum of amikacin includes broad activity against Gram-negative aerobic bacilli, including species of Pseudomonas aeruginosa, Escherichia coli, Klebsiella, Enterobacter, Serratia, and Proteus. It is resistant to degradation by many aminoglycoside-inactivating enzymes that neutralize gentamicins and tobramycins, making it valuable against resistant bacterial strains.
Main uses
Mikacin injection is indicated for the short-term treatment of serious infections caused by susceptible strains of Gram-negative bacteria. Clinical indications include bacteremia and septicemia, complicated bone and joint infections, severe central nervous system infections such as meningitis, intra-abdominal infections (including peritonitis), and complicated urinary tract infections.
It is also indicated for serious lower respiratory tract infections, including hospital-acquired pneumonia. In specific clinical scenarios, off-label usage may include targeted therapy for non-tuberculous mycobacterial (NTM) infections or complex multidrug-resistant tuberculosis protocols under direct infectious disease specialist oversight.
Dosing schedule
The administration of Mikacin must be individualized based on patient body weight, serum drug concentration monitoring, and kidney function assessments. The standard intravenous or intramuscular dosage for adults with normal renal function is 15 mg/kg per day, administered either as a single daily dose or divided into two or three equal doses given at equally spaced intervals.
Intravenous administration requires diluting the dose in a suitable parenteral solution, such as 0.9% Sodium Chloride Injection or 5% Dextrose Injection, and infusing it over a period of 30 to 60 minutes. Dosing schedules must be modified promptly in patients with renal insufficiency to avoid excessive accumulation of the drug in plasma.
What happens in the body
Following intramuscular injection, amikacin is rapidly absorbed, achieving peak serum concentrations within 0.5 to 1.5 hours. When administered via intravenous infusion over 30 minutes, peak serum concentrations are reached immediately at the end of the infusion. Amikacin distributes primarily into extracellular fluids, including serum, pleural fluid, pericardial fluid, and peritoneal fluid, with minimal penetration into normal cerebrospinal fluid.
Protein binding of amikacin remains low, typically under 10%. The terminal elimination half-life in adult patients with normal renal function ranges from 2 to 3 hours. Amikacin does not undergo significant hepatic metabolism and is excreted unchanged almost entirely (>90%) by glomerular filtration in the kidneys within 24 hours of administration.
First days of treatment
When starting treatment with Mikacin, therapy is usually initiated in a clinical or hospital setting. During the initial 24 to 48 hours, healthcare providers obtain baseline laboratory tests, including serum creatinine, blood urea nitrogen (BUN), and complete blood counts, to evaluate baseline renal function and systemic stability.
Therapeutic drug monitoring (TDM) is routinely initiated early in the treatment course. Blood samples are drawn to measure peak serum levels (to ensure therapeutic efficacy) and trough serum levels (to minimize nephrotoxic and ototoxic risk). Patients should expect frequent blood sampling and monitoring of fluid intake and urine output during the initial phase of therapy.
Compatibility with other medicines
Combining Mikacin with other pharmacologically active substances requires careful clinical evaluation. Concurrent or sequential use of other neurotoxic, nephrotoxic, or ototoxic agents–such as amphotericin B, cisplatin, vancomycin, capreomycin, polymyxin B, or colistin–increases the risk of severe organ toxicity and should be avoided whenever possible.
Concomitant administration of potent loop diuretics, such as furosemide or ethacrynic acid, enhances the risk of ototoxicity by altering aminoglycoside concentrations in serum and inner ear fluids. Additionally, physical incompatibility occurs when amikacin is mixed directly with beta-lactam antibiotics (such as penicillins or cephalosporins) in the same intravenous solution; these agents must be administered separately.
Adverse reactions
Adverse reactions associated with Mikacin therapy primarily involve renal, auditory, and vestibular systems. Ototoxicity can manifest as auditory loss (tinnitus, high-frequency hearing reduction, or permanent deafness) or vestibular instability (dizziness, vertigo, and loss of balance). Nephrotoxicity is commonly characterized by decreased glomerular filtration, rising serum creatinine concentrations, oliguria, or the presence of casts in the urine.
Other reported side effects include neuromuscular blockage leading to muscular weakness or respiratory depression, skin rashes, drug fever, headache, nausea, and injection site pain or phlebitis. Hypomagnesemia and other electrolyte imbalances have also been observed during extended administration.
Important precautions
Mikacin carries significant risks for nephrotoxicity, ototoxicity, and neuromuscular blockade. Renal function must be evaluated prior to initiating therapy and monitored regularly during treatment. Elderly patients, dehydrated patients, and those with pre-existing renal impairment face an elevated risk of severe adverse reactions and require reduced dosages accompanied by frequent serum drug level measurements.
Aminoglycosides can cause neuromuscular blockade, resulting in respiratory paralysis, particularly when administered to patients with myasthenia gravis or those receiving concomitant neuromuscular blocking agents or anesthetics. Dosage regimens must be strictly adjusted based on peak and trough concentrations to maintain safety margins.
Pregnancy, breastfeeding, and other groups
Amikacin crosses the placenta and can cause fetal harm when administered to pregnant women. Aminoglycosides demonstrate potential for complete, irreversible, bilateral congenital deafness in utero. Therefore, Mikacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Small amounts of amikacin are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug. In pediatric populations, particularly premature infants and neonates, renal immaturity results in a prolonged serum half-life, necessitating lower doses and extended dosage intervals.
Critical Safety Concerns
| Manifestation | Clinical Sign |
|---|---|
| Auditory toxicity | Tinnitus, perception of ear fullness, loss of high-tone hearing |
| Vestibular toxicity | Unsteadiness, dizziness, severe vertigo, ataxia |
| Renal impairment | Significant decrease in urine output, dark urine, fluid retention |
| Neuromuscular paralysis | Sudden muscle weakness, difficulty breathing, shallow respiration |
| Hypersensitivity | Severe cutaneous rash, urticaria, facial edema, wheezing |
Red flags
Patients receiving Mikacin therapy must be monitored continuously for symptoms indicating severe systemic reactions. Immediate medical intervention is mandatory if signs of auditory dysfunction arise, including persistent ringing in the ears, diminished hearing acuity, or sudden dizziness. These signs often indicate vestibular or cochlear nerve damage that may become irreversible if the medication is continued.
Prompt clinical evaluation is equally required if there is a sudden decrease in urinary output, significant swelling in the extremities, uncharacteristic weakness, or difficulty breathing. Anaphylactic reactions characterized by swelling of the face, lips, or throat, or widespread cutaneous blistering require immediate emergency medical care.
Storage and expiration
Mikacin Injection vials should be stored at controlled room temperature, between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Protect the product from light and avoid freezing. Store vials in their original outer carton until time of use.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Solutions that show signs of precipitation or significant color changes should not be used. Any unused portion of a single-dose vial must be properly discarded according to institutional protocols.
Common questions
Why is blood level monitoring necessary during treatment with Mikacin?
Therapeutic drug monitoring is essential to ensure that serum amikacin concentrations remain within the effective therapeutic range while avoiding toxic levels. Measuring peak levels verifies that the dose is sufficient to eliminate the bacterial infection, while measuring trough levels ensures the drug clears adequately between doses to minimize risks of kidney and inner ear damage.
Can Mikacin be mixed in the same intravenous bag with other antibiotics?
No, Mikacin should not be physically mixed with other antimicrobial agents, particularly beta-lactams like penicillins or cephalosporins, in the same infusion bag or syringe. Direct mixing can result in chemical inactivation of the aminoglycoside. If concurrent antibiotic therapy is prescribed, the medications must be administered at separate sites or infused at different times with adequate line flushing.
What measures are taken if a patient has impaired kidney function?
If renal impairment is present, the clearing of amikacin from the body is reduced. Healthcare providers compensate by either decreasing the individual dose size or extending the time interval between doses. Dosage adjustments are calculated using clearance formulas and guided by regular serum amikacin level measurements.
Are inner ear changes caused by Mikacin reversible?
Ototoxicity resulting from amikacin administration can involve damage to the auditory hair cells or vestibular structures, which is frequently irreversible. Early detection of symptoms, such as high-frequency hearing loss or tinnitus, is critical because damage may progress even after the drug is discontinued. Prompt discontinuation or dose adjustment upon early signs can help limit further injury.
How is a missed dose handled in a clinical setting?
Because Mikacin is administered by healthcare professionals in controlled medical environments, doses are scheduled precisely. If a dose is delayed or missed, the healthcare team adjusts the schedule based on clinical judgment and serum drug concentrations. Patients should not receive a double dose to compensate for a missed administration.
In accordance with FDA requirements.
Information on this page is for reference and does not replace an assessment by a licensed healthcare professional.
Additional information
| Dosage |
100 mg per 2 ml |
|---|---|
| Package |
10 injection ,20 injection ,30 injection |
| Ενεργός Ουσία |
Related products
Augmentin
$ 56,00 – $ 678,00Price range: $ 56,00 through $ 678,00
Active substance: amoxicillin, clavulanate
More Details
This product has multiple variants. The options may be chosen on the product page
Azee
$ 30,00 – $ 150,00Price range: $ 30,00 through $ 150,00
Active substance: Azithromycin
More Details
This product has multiple variants. The options may be chosen on the product page
Azee DT
$ 20,00 – $ 42,00Price range: $ 20,00 through $ 42,00
Active substance: Azithromycin
More Details
This product has multiple variants. The options may be chosen on the product page
Azeetop
$ 40,00 – $ 250,00Price range: $ 40,00 through $ 250,00
Active substance: Azithromycin
More Details
This product has multiple variants. The options may be chosen on the product page
Azithromycin DT
$ 60,00 – $ 972,00Price range: $ 60,00 through $ 972,00
Active substance: Azithromycin
More Details
This product has multiple variants. The options may be chosen on the product page
Chloramphenicol
$ 56,00 – $ 260,00Price range: $ 56,00 through $ 260,00
Active substance: chloramphenicol
More Details
This product has multiple variants. The options may be chosen on the product page
Chloromycetin
$ 52,00 – $ 242,00Price range: $ 52,00 through $ 242,00
Active substance: chloramphenicol
More Details
This product has multiple variants. The options may be chosen on the product page
Ciloxan Ophthalmic Solution
$ 50,00 – $ 63,00Price range: $ 50,00 through $ 63,00
Active substance: Ciprofloxacin hydrochloride
More Details
This product has multiple variants. The options may be chosen on the product page
